BreastNext

Understanding high-risk breast cancer patients such as those with early-onset or multiple diagnoses of breast cancer, male breast cancer, and/or with a family history of disease is made clearer with BreastNext, a 17 gene panel, offering more precision to identify and manage hereditary breast cancer.

Downloads

Quick Reference
Test Code 8820
Turnaround Time (TAT) 14-21 days
Number of Genes 17
Specimen Requirements Click here

Ordering Options

Why Is This Important?

Identifying patients with a genetic predisposition to cancer can allow informed recommendations and personalized medical management that significantly decrease cancer risks and improve overall survival rates.

  1. Option to modify frequency and initial age of mammogram and breast MRI
  2. Consideration of prophylactic mastectomy or other risk-reducing measures, as appropriate
  3. Option to tailor treatments (e.g. PARP inhibitors for BRCA1/BRCA2)
  4. Identify at-risk family members

When To Consider Testing

  • Early-onset breast cancer (diagnosed <45 years of age)
  • Triple negative (ER-/PR-/HER2/neu-) breast cancer diagnosed <60 years of age
  • Ovarian, Fallopian tube, or primary peritoneal cancer at any age
  • Bilateral or multiple primary breast cancers
  • Male breast cancer at any age
  • Ashkenazi Jewish descent with breast cancer at any age
  • 3 or more cases of breast, ovarian, pancreatic, and/or high-grade prostate cancer at any age
  • Known BRCA1 or BRCA2 mutation in the family

Mutation Distribution and Detection Rates*

* Excludes MUTYH carriers and CHEK2 p.l157T

Test Description

BreastNext analyzes 17 genes (listed above). All genes are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for PTEN (c.-1300 to c.-745). The BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) is detected by NGS and confirmed by PCR and agarose gel electrophoresis. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1 Gross deletion/duplication analysis for the covered exons and untranslated regions of all 17 genes is performed using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray.

 

1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.

View Full Menu

Search Results

Start your search...